Nelarabine (Reach) TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: lebrikizumab
Brand name
(ARTG)
: NELARABINE-REACH nelarabine 250 mg/50 mL solution for infusion vialDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Nelarabine is indicated for the treatment of patients with relapsing /refractory T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment.,Due to the small patient populations in these disease settings, the information to support these indications is based on limited data..
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Intravenous Infusion
- Clear colourless solution.
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 24 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 pack
- 6 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient lebrikizumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
